Pharsight

Aptiom generic

Aptiom is an anti-seizure drug owned by Sunovion Pharms Inc. It contains the active ingredient eslicarbazepine acetate and was first authorised for market use on 8 November 2013. Aptiom holds a total of 11 patents, none of which have expired.

When will Aptiom generic be available?

The generic versions of Aptiom are expected to be released after 24 August, 2032. This date marks the expiration of the last patent registration under the name 'Treatments involving eslicarbazepine acetate or eslicarbazepine'.

Aptiom uses

Aptiom is used in the treatment of partial-onset seizures. It is particularly effective in patients with refractory partial-onset seizures, those with epilepsy who have been previously treated with oxcarbazepine, and those suffering from or susceptible to absence seizures.

Aptiom patent expiration

Aptiom has inherited a spectrum of 11 patents that present different aspects of its formulation and usage. These patents will expire sequentially, with the final one expiring on 24 August, 2032. You can find the details of the Aptiom generic release date based on these patents below:

EPO Oppostions filed on Aptiom

Aptiom dosage

Want to ask something?